In addition, the gene was considered to be related to Crohn’s disease, and the development of related drugs was in a phase II clinical trial.105 Another example was denosumab, which is a drug marketed for the treatment of osteoporosis in postmenopausal women, targeting the gene TNFSF11 (tumor necrosis factor superfamily, member 11), also known as RANKL. Denosumab is a RANKL inhibitor that functions by preventing the development of osteoclasts. Here, TNFSF11 is linked to osteoporosis.